1DEMETRI GD, VAN OOSTEROM AT, GARRETT CR, et al. Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial[ J]. Lancet, 2006, 368 (9554) : 1329 - 1338.
2GOODMAN VL, ROCK EP, DAGHER R, et al. Approval summary: sunitinib for the treatment of imatinib refractory or intolerant gastrointestinal stromal tumors and advanced renal cell carcinoma[J]. Clin Cancer Res, 2007,13 (5) : 1367 - 1373.
3JANEWAY KA, MATTHEWS DC, BUTRYNSKI J E, et al. Sunitinib treatment of pediatric metastatic GIST after failure of imatinib [ J ]. J Clin Oncol, 2006, 24 ( 18 S) :9519.
4MOTZER RJ. , HUTSON TE. , TOMCZAK P, et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma [ J ]. N Engl J Med, 2007, 356(2) :115 - 124.
5MOTZER RJ, RINI BI, BUKOWSKI RM, et al. Sunitinib in patients with metastatic renal cell carcinoma[J]. JAMA, 2006, 295 (21) :2516 - 2524.
6ROCK EP, GOODMAN V, JIANG JX, et al. Food and Drug Administration drug approval summary: sunitinib malale for the treatment of gastrointestinal stromal tumor and advanced renal celt carcinoma [J]. Oncologist, 2007, 12 ( 1 ) : 107 - 113.
7ROSENBERG JE, MOTZER RJ, M1CHAELSON, et al. Sunitinib therapy for patients (pts) with metastatic renal cell carcinoma ( mRCC ) : updated results of two phase II trials and prognostic factor analysis for survival[J]. J Clin Oncol, 2007, .25(18S) :5095.
8DE MULDER PH, ROIGAS J, GILLESSEN S, et al. A phase 11 study of sunitinib administered in a continuous daily regimen in patients with cytokine-refractory metastatic renal cell carcinoma (mRCC)[J]. J Clin Oncol , 2006, 24(18S):4529.
9GEORGE S, BLAY JY, CASALI PG, et al. Continuous daily dosing(CDD) of sunitinib malate(SU) compares favorably with intermittent dosing in pts with advanced GIST[ J]. J Clin Oncol, 2007, 25 (18S) :10015.
10COONEY MM, GARCIA J, BRELL J, et al. A phase 1 study of bevacizumab in combination with sunitinib in advanced solid tumors [ J ]. J Clin Oncol, 2007,25 ( 18 S ) : 15532.
